Henry I. Miller


Henry I. Miller, MS, MD, was the Robert Wesson Fellow in Scientific Philosophy and Public Policy at the Hoover Institution. His research focused on public policy toward science and technology, encompassing a number of areas, including pharmaceutical development, genetic engineering in agriculture, models for regulatory reform, and the emergence of new viral diseases.

Miller served for fifteen years at the US Food and Drug Administration (FDA) in a number of posts. He was the medical reviewer for the first genetically engineered drugs to be evaluated by the FDA and thus instrumental in the rapid licensing of human insulin and human growth hormone. Thereafter, he was a special assistant to the FDA commissioner and the founding director of the FDA's Office of Biotechnology. During his government service, Miller participated frequently on various expert and policy panels as a representative of the FDA or the US government. As a government official, Miller received numerous awards and citations.

During his time at the Hoover Institution, Miller has become well known not only for his contributions to scholarly journals but also for his articles and books that make science, medicine, and technology accessible. His work has been widely published in many languages. Monographs include Policy Controversy in Biotechnology: An Insider's View; To America's Health: A Model for Reform of the Food and Drug Administration; and The Frankenfood Myth: How Protest and Politics Threaten the Biotech Revolution. Barron's selected The Frankenfood Myth as one of the 25 Best Books of 2004. In addition, Miller has published extensively in a wide spectrum of scholarly journals and popular publications worldwide, including The Lancet, Journal of the American Medical Association, Science, the Nature family of journals, Chronicle of Higher Education, Forbes, National Review, Wall Street Journal, New York Times, the Guardian, Defining Ideas, and the Financial Times. He was a regulator contributor to Forbes.com and frequently appeared on the nationally syndicated radio programs of John Batchelor and Lars Larson.

Miller was selected by the editors of Nature Biotechnology as one of the people who had made the "most significant contributions" to biotechnology during the previous decade. He serves on numerous editorial boards.

Filter By:



Recent Commentary

Blank Section (Placeholder)

Turning over a New (Organic) Leaf

by Henry I. Miller, John Cohrssenvia Hoover Digest
Monday, October 29, 2018

Bioengineered crops help farmers and feed increasing numbers of people, but the organic industry still rejects them. New organic labels could, and should, make room for science.

Analysis and Commentary

Buying Organic? You’re Getting Ripped Off

by Henry I. Millervia Daily Caller
Thursday, August 30, 2018

False and misleading advertising by the organic agriculture and food industries is out of control and sowing consumer fear, confusion and mistrust.

Analysis and Commentary

Feds Battle Opioid Abuse With A Circular Firing Squad

by Henry I. Miller, Josh Bloomvia Daily Caller
Wednesday, August 29, 2018

In her classic treatise on blunders in public policy, Barbara Tuchman famously wrote: Mankind, it seems, makes a poorer performance of government than of almost any other human activity. In this sphere, wisdom, which may be defined as the exercise of judgment acting on experience, common sense and available information, is less operative and more frustrated than it should be.

Analysis and Commentary

EU Court Falls Short On Both Logic And The Law

by Henry I. Miller, Drew L. Kershenvia Investors Business Daily
Monday, August 27, 2018

"The law is an ass" is an observation made popular by Charles Dickens in "Oliver Twist" (1838). Never was it more true 180 years later, when, on July 25, 2018, the Court of Justice of the European Union (CJEU) ruled that the modern techniques of genetic breeding of crops and animals are subject to the EU regulations that govern so-called "GMOs," genetically modified organisms.


Mandatory Mislabeling

by Drew L. Kershen, Henry I. Millervia City-Journal
Friday, August 10, 2018

Bioengineered foods need not be labeled as such unless there are compelling health and safety reasons for doing so.

Analysis and Commentary

Got Skin Cancer? Blame The FDA

by Renata H. Mullen, Henry I. Millervia Fox News
Monday, August 6, 2018

Americans are getting skin cancer – and sometimes dying from it – at an alarming rate, while the U.S. Food and Drug Administration irresponsibly refuses to approve state-of-the-art sunscreens that could do a much better job protecting us from the sun’s cancer-causing rays.


The Organic Industry Is Lying To You

by Henry I. Millervia The Wall Street Journal
Sunday, August 5, 2018

[Subscription Required] In the mold of “Mad Men’s” Don Draper, clever ad execs know a thing or two about manipulating consumer ignorance, confusion and even fear to sell a product. Nowhere is this truer than modern food advertising, where dubious health claims and questionable scientific assertions abound.

Analysis and Commentary

The Future Of Food Needs Transparency And Integrity: A Response

by Henry I. Millervia Investors Business Daily
Friday, August 3, 2018

Regarding the Commentary by Stacey Malkan and Carey Gillam, "The Future Of Food Needs Transparency And Integrity," July 24: If we have entered the post-truth era, in which debate is framed largely by assertions disconnected from evidence and by the endless repetition of mendacious talking points, Malkan, Gillam and their lobbying organization, U.S. Right to Know, fit right in. Like all effective but dishonest propagandists, they take snippets of truth and combine them in ways that create falsehoods.

Analysis and Commentary

An Endangered Frog Ends Up In The Regulatory Swamp

by Henry I. Millervia The Daily Caller
Wednesday, August 1, 2018
The Trump administration unveiled its main effort to overhaul the Endangered Species Act on July 19, when the Interior and Commerce Departments proposed important changes to the law.
Analysis and Commentary

Drug Reciprocity Could Save Lives In The U.S.

by Henry I. Miller, John Cohrssenvia City Journal
Tuesday, July 31, 2018
President Trump recently signed legislation permitting terminally ill patients to obtain experimental drugs directly from manufacturers, without having to wait for full approval.